Table 5 Recommendations of intravesical therapy for high risk patientsa
Guideline ID | High risk | |||||||
|---|---|---|---|---|---|---|---|---|
Induction | Maintenance | |||||||
Be recommended | Be recommended | Course of treatment | ||||||
Chemotherapy | BCG | Chemotherapy | BCG | Chemotherapy | BCG | |||
SOR/LOE | SOR/LOE | SOR/LOE | SOR/LOE | Course | SOR/LOE | Course | SOR/LOE | |
ESMO, 2014 [8] | −/− | −/− | −/− | −/− | – | −/− | – | −/− |
NICE, 2015 [9]b | −/− | A/high-very low | −/− | A/high-very low | – | −/− | – | −/− |
CUA, 2015 [10] | −/− | A/− | −/− | B/− | – | −/− | Full dose, 3 years | B/− |
AUA/SUO, 2016 [3] | −/− | Strong/B | −/− | Moderate/B | – | −/− | 3 years | Moderate/B |
JUA, 2016 [11] | −/− | −/− | −/− | −/− | – | −/− | – | −/− |
EAU, 2018 [12] | −/− | −/− | −/− | Strong/1a-1b | – | −/− | Full dose, 1–3 years Three-weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months | Strong/1a-1b |
ICUD/SIU, 2018 [13] | B/2 | A/1 | C/2 | B/2 | 1 year | C/2 | 3 years | B/2 |
CRHA/CPAM, 2018 [14] | A/1a | A/1a | A/1a | A/1a | Monthly for 6–10 months | A/1a | Full dose, 3 years | B/1b |
NCCN, 2019 [15]c | B/2A | A/1 | B/2A | A/2A | – | B/2A | 3 years Three-weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months | B/2A |